ORIC Pharmaceuticals Inc., a South San Francisco-based company going after treatment-resistant solid tumors with an oral glucocorticoid receptor inhibitor, ORIC-101, has completed a $50 million series C financing it said will support the clinical advancement of the asset and work targeting mechanisms of resistance in cancer.